logo

Branimir Sikic, MD

Branimir Sikic, MD

Hematology Stanford, CA

Professor, Medicine - Oncology, Stanford University Medical Center

Office Address

Office Map
  • 300 Pasteur Dr
    Stanford Comp Cancer Ctr, Clinic C
    Stanford, CA 94305
    Phone: (650) 723-4000

Dr. Sikic's Clinical Specialties & Interests

  • Hematology: General Hematology

Dr. Sikic's Education & Medical Training

  • Georgetown University HospitalGeorgetown University HospitalResidency, Internal Medicine
  • U of Chicago, Pritzker Sch of MedUniversity of Chicago Pritzker School of MedicineMedical School

Dr. Sikic's Certifications & Licensure

  • CA State Medical LicenseCA State Medical License1979 - 2015
  • American Board of Internal MedicineAmerican Board of Internal MedicineInternal Medicine
  • American Board of Internal MedicineAmerican Board of Internal MedicineMedical Oncology

Dr. Sikic's Awards, Honors, & Recognition

  • American Society of Clinical OncologistsFellow (FASCO)American Society of Clinical Oncologists, 2010

Dr. Sikic's Publications & Presentations

PubMed | Citations by Web of Science®

Grant Support

  • Protocol Specific Research Support
    Protocol Specific Research SupportNational Cancer Institute
    2010 - 2011
  • Taxane Resistance In Breast And Ovarian Cancer Cells
    Taxane Resistance In Breast And Ovarian Cancer CellsNational Cancer Institute
    2007 - 2011
  • Study Of Oblimersen (Genasensetm, G3139) In Advanced Malignancies
    Study Of Oblimersen (Genasensetm, G3139) In Advanced MalignanciesNational Center For Research Resources
    2006 - 2006
  • Treatment Of Advanced Solid Malignancies
    Treatment Of Advanced Solid MalignanciesNational Center For Research Resources
    2005 - 2005
  • Study Of Oblimersen In Combination With Gemcitabine In Advanced Malignancies
    Study Of Oblimersen In Combination With Gemcitabine In Advanced MalignanciesNational Center For Research Resources
    2005 - 2005
  • A Phase I Study Of Oblimersen (Genasense TM, G3139)
    A Phase I Study Of Oblimersen (Genasense TM, G3139)National Center For Research Resources
    2004 - 2004
  • Phase I Study:  Weekly Bms-188797 Alone &With Carboplat
    Phase I Study: Weekly Bms-188797 Alone &With CarboplatNational Center For Research Resources
    2004 - 2004
  • Phase I Study Of Bms-310705 Given Every Three Weeks
    Phase I Study Of Bms-310705 Given Every Three WeeksNational Center For Research Resources
    2004 - 2004
  • A Phase I Study Of ZD1839 (Iressa Tm) With Oxaliplatin
    A Phase I Study Of ZD1839 (Iressa Tm) With OxaliplatinNational Center For Research Resources
    2004 - 2004
  • Regulation Of The Human MDR1 Gene
    Regulation Of The Human MDR1 GeneNational Cancer Institute
    2002 - 2005
  • Gene Expression Profiling Of Unknown Primary Cancers
    Gene Expression Profiling Of Unknown Primary CancersNational Cancer Institute
    2001 - 2003
  • Ly335979 &Mitoxantrone In  Prostate Cancer
    Ly335979 &Mitoxantrone In Prostate CancerNational Center For Research Resources
    2000 - 2001
  • Phase I Trial Of Doxil, Paclitaxel And Valspodar PSC 833
    Phase I Trial Of Doxil, Paclitaxel And Valspodar PSC 833National Center For Research Resources
    2000 - 2001
  • Phase I Trial Of Oral Paclitaxel And Valspodar (Psc 833)
    Phase I Trial Of Oral Paclitaxel And Valspodar (Psc 833)National Center For Research Resources
    2000 - 2001
  • Modulation Of Multidrug Resistance Mechanisms
    Modulation Of Multidrug Resistance MechanismsNational Cancer Institute
    1999 - 2002
  • Phase I Trial Of Antisense Inhibitor Of Protein Kinase C Alpha In Can
    Phase I Trial Of Antisense Inhibitor Of Protein Kinase C Alpha In CanNational Center For Research Resources
    1999 - 2001
  • CGP 64128a Administered As A Continuous Infusion In Patients With Cancer
    CGP 64128a Administered As A Continuous Infusion In Patients With CancerNational Center For Research Resources
    1998 - 1999
  • Phase II Of ISIS 3521 In Patients With Ovarian Carcinoma
    Phase II Of ISIS 3521 In Patients With Ovarian CarcinomaNational Center For Research Resources
    1998 - 2001
  • Phase I Protein Kinase, Carboplatin And Paclitaxel Chemo. For Cancer
    Phase I Protein Kinase, Carboplatin And Paclitaxel Chemo. For CancerNational Center For Research Resources
    1998 - 2001
  • Paclitaxel And PSC 833 In Metastatic Colorectal Carcinoma
    Paclitaxel And PSC 833 In Metastatic Colorectal CarcinomaNational Center For Research Resources
    1998 - 2001
  • Phase I Trial Of Doxorubicin, Paclitaxel, And PSC 833
    Phase I Trial Of Doxorubicin, Paclitaxel, And PSC 833National Center For Research Resources
    1997 - 2001
  • Phase I Clinical Trial Of Cgp64128a Administered As A Continuous Infusion
    Phase I Clinical Trial Of Cgp64128a Administered As A Continuous InfusionNational Center For Research Resources
    1997 - 1997
  • Phase II Clinical Trial Of Paclitaxel &Psc 833 In Metastatic Colorectal Cancer
    Phase II Clinical Trial Of Paclitaxel &Psc 833 In Metastatic Colorectal CancerNational Center For Research Resources
    1997 - 1997
  • Tubulin Genes And Drug Resistance
    Tubulin Genes And Drug ResistanceNational Cancer Institute
    1996 - 1998
  • Trial Of Doxorubicin, Paclitaxel, And PSC 833
    Trial Of Doxorubicin, Paclitaxel, And PSC 833National Center For Research Resources
    1996 - 1996
  • Phase 1 Trial Of Taxol And PSC-833 Chemotherapy
    Phase 1 Trial Of Taxol And PSC-833 ChemotherapyNational Center For Research Resources
    1996 - 1996
  • Expression And Modulation Of Multidrug Resistance
    Expression And Modulation Of Multidrug ResistanceNational Cancer Institute
    1990 - 1998
  • Cyano-Morpholino Anthracyclines
    Cyano-Morpholino AnthracyclinesNational Cancer Institute
    1986 - 1988

Hospital Affiliations

Insurance Accepted

  • BCBS Blue Card PPO
  • BCBS California PPO
  • Blue Shield California PPO
  • CIGNA HMO
  • CIGNA Open Access
  • CIGNA PPO
  • First Health PPO
  • Great West PPO
  • Health Net California Large Group PPO
  • Multiplan PHCS PPO
  • Multiplan PHCS PPO - Kaiser
  • Multiplan PPO
  • United Healthcare - Direct Choice Plus POS
  • United Healthcare - Direct Options PPO

Alternate Names

  • Dr. Branimir Sikic, Dr. Branimir Sikic, MD, Dr. B Sikic, Dr. Branimir I. Sikic

20 Colleague Invites!
Is this you? If so, register to see 20 messages.

Physicians, view Dr. Sikic's full Doximity profile to:

  • Trade HIPAA-secure messages
  • Send and receive online faxes
  • Refer a patient
  • See their complete CV